GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

Rhea-AI Summary

GlycoMimetics (Nasdaq: GLYC) announced a key opinion leader event on June 4, 2024, to discuss comprehensive results from their pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML). The event will feature Dr. Daniel DeAngelo of Harvard Medical School, who will present the findings and discuss the current AML treatment landscape and unmet needs. The event will start at 8:30am ET and will be accessible via phone and live webcast.

Positive

• GlycoMimetics is hosting a high-profile event featuring key opinion leader, Dr. Daniel DeAngelo, which can enhance the company's credibility.
• The event discusses pivotal Phase 3 study results, indicating progress in their clinical pipeline.
• Focus on relapsed/refractory AML highlights the company's dedication to addressing unmet medical needs.
• A webcast replay will be accessible for 30 days, increasing the event's reach and visibility.

Negative

• The press release does not disclose specific Phase 3 study results, which might raise concerns about the data's impact.
• Dependence on a single event to drive investor interest may not sustain long-term stock performance.
• No information on regulatory approval process timelines, creating uncertainty for investors.

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company’s pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML).

The event will feature the study’s principal investigator Daniel DeAngelo, M.D., Ph.D., Professor of Medicine, Harvard Medical School, and Chief of the Division of Leukemia, Dana-Farber Cancer Institute, who will discuss results from the pivotal Phase 3 study of uproleselan, along with the current AML treatment landscape and unmet patient need.

To access the event by phone, please go to this registration link to obtain the dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.

A live webcast of the call will be available on the “Investors” tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call.

About AML

AML is the most common acute leukemia in adults. A cancer of the bone marrow, nearly 21,000 people in the United States are diagnosed with AML each year. Despite the availability of multiple treatments, disease prognosis is poor, and new treatment options are needed to improve outcomes. Newly diagnosed AML has the lowest 5-year survival rate of all leukemias at 31.7%. The five-year survival rate for people with relapsed/refractory disease is only 10%.

About Uproleselan

Discovered and developed by GlycoMimetics, uproleselan (yoo’ pro le’se lan) is an investigational, first-in-class E-selectin antagonist. GlycoMimetics has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA) and Breakthrough Therapy designation from the Chinese National Medical Products Administration for uproleselan as a potential treatment for adult AML patients with relapsed or refractory disease. E-selectin is a leukocyte adhesion molecule constitutively expressed on endothelial cells of the vasculature and bone marrow. In AML, there is evidence that E-selectin–ligand interaction between endothelial cells in the protective niche of the Bone Marrow microEnvironment (BME) and leukemic stem cells and blasts promotes leukemic cell survival and hides them from AML therapies. Uproleselan is designed to disrupt E-selectin binding and prevent leukemic myeloid cells using the protective niche of the BME.

About GlycoMimetics, Inc.

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. GlycoMimetics is leveraging its differentiated expertise with this scientific approach in order to advance its pipeline of wholly owned drug candidates. The company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the analysis and presentation of data from the pivotal Phase 3 study of uproleselan; current AML treatment landscape and unmet patient need; and the potential benefits and impact of uproleselan. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2024, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529592940/en/

Investor:

Argot Partners

Leo Vartorella

212-600-1902

Glycomimetics@argotpartners.com

Source: GlycoMimetics, Inc.

FAQ

What event is GlycoMimetics hosting on June 4, 2024?

GlycoMimetics is hosting a key opinion leader event to discuss the pivotal Phase 3 study results of uproleselan in relapsed/refractory acute myeloid leukemia (AML).

Who will feature in GlycoMimetics' event on June 4, 2024?

Dr. Daniel DeAngelo, Professor of Medicine at Harvard Medical School and Chief of the Division of Leukemia at Dana-Farber Cancer Institute, will feature in the event.

How can I access GlycoMimetics' event on June 4, 2024?

The event can be accessed by phone with registration or via a live webcast available on the GlycoMimetics website.

What is the focus of GlycoMimetics' event on June 4, 2024?

The focus is on the comprehensive results from the pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML).

What time does GlycoMimetics' event on June 4, 2024, begin?

The event begins at 8:30am ET.